


1/19


LCMS ANALYSIS OF RECOMBINANT PEPTIDE VARIANTS

1: TOF MS ES+
2305+1153
1.98e3
Area



SEQ ID NO: 26

1: TOF MS ES+
2093+1047
1.78e3
Area



SEQ ID NO: 8

FIG. 1A

2/19




FIG. 1B

3/19




FIG.1C

4/19




FIG. 2

5/19




FIG. 3A

6/19




FIG. 3B

7/19




FIG. 4A

8/19





FIG. 4B

9/19



* $p < 0.01$

** $p < 0.005$

*** $p < 0.0005$

SEQ ID NO: 31

FIG. 4C

10/19




FIG. 5A

11/19




FIG. 5B




FIG. 6A

13/19

CHEMICALLY SYNTHESIZED PEPTIDES IN MOUSE INTESTINAL SECRETION MODEL





FIG. 6B


14/19



*p<0.05 as compared to "vehicle" value

FIG. 7

15/19



SEQ ID NO: 28 Indomethacin

FIG. 8A

16/19

VISCERAL ANTINOCICEPTIVE EFFECTS OF
SEQ ID NO: 31 IN A MOUSE WRITHING ASSAY




FIG. 8B

17/19





FIG. 9

18/19

MINIMUM SYSTEMIC ABSORPTION OF SEQ ID NO: 31
(BASED ON ELISA)




* Limit of detection 0.061 µg/ml
Dosing at 10 mg/kg

FIG. 10A

19/19

MINIMUM SYSTEMIC ABSORPTION OF
SEQ ID NO: 31 (BASED ON LC/MS)



* Limit of detection 0.0063 µg/ml (0.6 nM)

* Dosing at 10 mg/kg

FIG 10B